The average sales price (ASP) decrease proposed by our friends at Medicare could change the face of private practice infusion suites nationwide. This would be bad for patient care; almost as importantly, this decrease would be very bad for the rheumatology business.
While it may have taken 17 years to repeal the Sustainable Growth Rate formula, according to Lemeneh Tefera, MD, MSc, Medical Officer at the Centers for Medicare & Medicaid Services (CMS), it was a surprisingly bipartisan bill.

Results 1 - 2 of 2
  • American Health and Drug Benefits
  • Association for Value Based Cancer Care
  • Lynx CME
  • Oncology Practice Management
  • Rheumatology Practice Management